Search research articles
Contact Us
Filters
Showing results (201-210 of 418) with videos related to
Page
of 42
Sort By:
European Urology
|
November 6, 2016
Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered
Grant D Stewart, Michael Aitchison, Axel Bex, et al.
Journal of Translational Medicine
|
August 5, 2020
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials
Paolo A Ascierto, Antoni Ribas, James Larkin, et al.
Cancer Treatment Reviews
|
March 4, 2026
Erratum to "Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review". [Cancer Treat. Rev. 140 (2025) 103024]
Natalie Charnley, Kate Fife, Daniel Y C Heng, et al.
Pigment Cell & Melanoma Research
|
November 21, 2017
Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib
Matthew J Wongchenko, Antoni Ribas, Brigitte Dréno, et al.
Frontiers in Oncology
|
June 26, 2023
A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma
Sebastian Bauer, James Larkin, F Stephen Hodi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 19, 2019
Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma
Sophia Kreft, Anja Gesierich, Thomas Eigentler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2020
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era
Michele Maio, Omid Hamid, James Larkin, et al.
Clinical Genitourinary Cancer
|
August 6, 2024
Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results
Paul Nathan, Balaji Venugopal, Jamshed Ali, et al.
Melanoma Research
|
February 24, 2021
The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials
Roger Olofsson Bagge, Lars Ny, Paolo A Ascierto, et al.
The Journal of Pathology
|
April 27, 2013
Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma
Simon J Furney, Samra Turajlic, Gordon Stamp, et al.
Page
of 42
Search research articles
Search
Showing results (201-210 of 418) with videos related to
Sort By:
Page
of 42
European Urology
|
November 6, 2016
Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered
Grant D Stewart, Michael Aitchison, Axel Bex, et al.
Journal of Translational Medicine
|
August 5, 2020
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials
Paolo A Ascierto, Antoni Ribas, James Larkin, et al.
Cancer Treatment Reviews
|
March 4, 2026
Erratum to "Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review". [Cancer Treat. Rev. 140 (2025) 103024]
Natalie Charnley, Kate Fife, Daniel Y C Heng, et al.
Pigment Cell & Melanoma Research
|
November 21, 2017
Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib
Matthew J Wongchenko, Antoni Ribas, Brigitte Dréno, et al.
Frontiers in Oncology
|
June 26, 2023
A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma
Sebastian Bauer, James Larkin, F Stephen Hodi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 19, 2019
Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma
Sophia Kreft, Anja Gesierich, Thomas Eigentler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2020
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era
Michele Maio, Omid Hamid, James Larkin, et al.
Clinical Genitourinary Cancer
|
August 6, 2024
Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results
Paul Nathan, Balaji Venugopal, Jamshed Ali, et al.
Melanoma Research
|
February 24, 2021
The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials
Roger Olofsson Bagge, Lars Ny, Paolo A Ascierto, et al.
The Journal of Pathology
|
April 27, 2013
Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma
Simon J Furney, Samra Turajlic, Gordon Stamp, et al.
Page
of 42